Aurora Kinase
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
CSN12727 | ZM-447439 | 331771-20-1 | ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM 130 nM respectively 8 fold selectivity than Aurora C MEK1 Src |
CSN26598 | Tripolin A | 1148118-92-6 | Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive Aurora A kinase inhibitor, with IC50 values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively[1]. |
CSN12326 | Tozasertib | 639089-54-6 | Tozasertib is the inhibitor of Aurora-A, -B, -C kinases with Ki values of 0.6, 18, 4.6 nM respectively. |
CSN23149 | TC-A 2317 hydrochloride | 1245907-03-2 | TC-A2317 HCl is an Aurora kinase A inhibitor. |
CSN16128 | TAK-901 | 934541-31-8 | TAK-901 is an inhibitor of Aurora AB with IC50 of 21 nM15 nM |
CSN20031 | (Z)-Orantinib | 210644-62-5 | SU6668 is a cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFR, VEGFR2 (Flk-1KDR), FGFR1 activity in vitro (IC50 0.01, 0.1, 3.9, and 3.8 M, respectively) and PDGFVEGFbFGF-mediated angiogenesis and tumor development. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target serthr kinases Aurora A, Aurora B, TBK1 (NAKT2K), and AMPK (IC50 0.85, 0.047, 1.4, and 1.8 M, respectively), as well as non-receptor TKs Lyn and Yes (IC50 4.3 and 5.8 M, respectively). |
CSN27599 | SP-96 | 2682114-54-9 | SP-96 is a highly selective and non-ATP-competitive Aurora A/B inhibitor with IC50 values of 0.316nM 18.975 nM for Aurora A and Aurora B, respectively. |
CSN18798 | SNS-314 mesylate | 1146618-41-8 | SNS-314 is a potent and selective inhibitor of Aurora A Aurora B and Aurora C with IC50 of 9 nM 31 nM and 3 nM respectively |
CSN13118 | SCH-1473759 | 1094069-99-4 | SCH-1473759 is a sub-nanomolar Aurora AB inhibitor with IC50 of 4 nM and 13 nM respectively |
CSN17462 | SCH-1473759 hydrochloride | 1094067-13-6 | SCH-1473759 HCl is a sub-nanomolar Aurora A/B inhibitor with IC50 of 4 nM and 13 nM, respectively. |
CSN15807 | Reversine | 656820-32-5 | Reversine a synthetic purine analogue26-disubstituted purine is a potent human A3 adenosine receptor antagonist with Ki of 066 M and a pan-aurora ABC kinase inhibitor with IC50 of 12 nM13 nM20 nM respectively |
CSN12811 | PHA-680632 | 398493-79-3 | PHA-680632 is potent inhibitor of Aurora A B and C with IC50 of 27 nM 135 nM and 120 nM respectively |
CSN18615 | PF-03814735 | 942487-16-3 | PF-03814735 is a potent orally bioavailable reversible small-molecule Aurora kinase inhibitor with IC50 of 08 5 10 and 22 nM for Aurora A Aurora B Flt 1 and FAk respectively |
CSN25344 | NU6140 | 444723-13-1 | NU6140 is a selective CDK2 inhibitor with IC50 value of 0.94μM, as well as potently inhibits Aurora kinase A/B with IC50 values of 0.035 and 0.067μM, respectively. |
CSN12363 | MLN8054 | 869363-13-3 | MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM and exhibits more than 40-fold selective for Aurora A than Aurora B |
CSN16817 | MK-8745 | 885325-71-3 | MK-8745 is a potent and selective Aurora an inhibitor with IC50 of 06 nM more than 450-fold selectivity for Aurora A over Aurora B |
CSN17389 | MK-5108 | 1010085-13-8 | MK-5108 is a potent and highly selective Aurora inhibitor with IC50 of 0064 14 and 12 nM for Aurora A B and C |
CSN11355 | Maleic Acid | 110-16-7 | Maleic acid is used in the synthesis of pyridoindolones as potent inhibitors of Aurora kinases. It is a reagent in the preparation of TiO2carbon nanotube composites. |
CSN13761 | Hesperadin | 422513-13-1 | Hesperadin is a potent and ATP-competitive inhibitor of Aurora B kinase with IC50 of 250 nM |
CSN12395 | GSK-1070916 | 942918-07-2 | GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora BC with IC50 of 35 nM65 nM and displays 100-fold selectivity against the closely related Aurora A-TPX2 complex IC50490 nM |
CSN14824 | Derrone | 76166-59-1 | Derrone, a natural product isolated and purified from the herbs of Cudrania tricuspidata, may be interesting antimicrobial agents to be used against infectious diseases caused by many pathogens, and is an Aurora kinase inhibitor, it can significantly inhibit the formation and growth of MCF7 tumor spheroids. |
CSN24802 | BPR1K871 | 2443767-35-7 | DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss. |
CSN12423 | Danusertib | 827318-97-8 | Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. |
CSN17118 | CYC-116 | 693228-63-6 | CYC116 is a potent inhibitor of Aurora with Ki of 80 nM92 nM for Aurora AB |
CSN16269 | CTX-0294885 | 1439934-41-4 | CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent. CTX-0294885 is a broad spectrum kinase inhibitor that inhibited FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively) in an initial screen. |
CSN50650 | CD532 | 1639009-81-6 | CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer. |
CSN27200 | CCT241736 | 1402709-93-6 | CCT241736 is a dual FLT3/Aurora kinase A/B inhibitor with IC50 values of 0.035μM, 0.015μM and 0.1μM, respectively. |
CSN17149 | CCT 137690 | 1095382-05-0 | CCT137690 is a potent inhibitor of Aurora kinases IC50 values are 0015 0019 and 0025 M at Aurora A Aurora C and Aurora B respectively |
CSN16415 | CCT129202 | 942947-93-5 | CCT129202 is a Aurora kinase inhibitor with IC50 of 0042 0022 0198 005 and 0227 0064 M for Aurora A Aurora B and Aurora C respectively |
CSN16205 | BI-847325 | 1207293-36-4 | BI-847325 is a selective and orally bioavailable dual MEKAurora kinase inhibitor with IC50 of 3 nM Xenopus laevis Aurora B 25 nM human Aurora A 15 nM human Aurora C 25 nM human MEK1 and 4 nM human MEK2 respectively |
CSN17268 | Barasertib-HQPA | 722544-51-6 | AZD1152-HQPA is the active metabolite of AZD-1152 and a highly selective Aurora B inhibitor with IC50 of 0.37 nM, 100 fold selective for Aurora B over Aurora A. |
CSN23770 | Aurora kinase inhibitor-3 | 879127-16-9 | Aurora kinase inhibitor III is a potent ATP-competitive aurora related kinase (also designated ARK) inhibitor with IC50 value of 42 nM for Aurora A kinase. |
CSN12380 | TCS7010 | 1158838-45-9 | Aurora an inhibitor I is a potent and selective inhibitor of Aurora A with IC50 of 34 nM in a cell-free assay It is 1000-fold selective for Aurora A than Aurora B |
CSN12715 | AT9283 | 896466-04-9 | AT9283 is a multi-targeted inhibitor with IC50s of 4 12 11 and approximate 3 nM for Bcr-Abl T315I JAK2 and JAK3 Aurora A and Aurora B respectively |
CSN26521 | (Z)-SKI V | 927429-51-4 | and a Kd of 3.06 μM. (Z)-SKI V inhibits Aurora A with an IC50 of 1.34 μM. (Z)-SKI V, a benzofuran derivative, has extensive cytotoxic effects on cancer cell lines[1]. |
CSN16543 | AMG 900 | 945595-80-2 | AMG-900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora ABC with IC50 of 5 nM4 nM 1 nM and is 10-fold selective for Aurora kinases than p38 Tyk2 JNK2 Met and Tie2 |
CSN13457 | Alisertib | 1028486-01-2 | Alisertib is a selective Aurora inhibitor with IC50 of 12 nM with 200-fold higher selectivity for Aurora A than Aurora B |